Kyverna Therapeutics Inc
Veridion Score
Composite trend over time
Why is KYTX moving today?
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for KYTX.
KYTX insider activity
Kyverna Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $1.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | 2026-05-27 | Shaw Christi | Insider | sell | $8.59 | 4,194 | 66,741 | $36K | SEC Form 4 |
| 2025-12-22 | 2025-12-18 | Westlake BioPartners Fund I, L.P. | Insider | buy | $7.50 | 133,333 | 869,317 | $1000K | SEC Form 4 |
| 2025-12-22 | 2025-12-18 | SEIDENBERG BETH C | Insider | buy | $7.50 | 133,333 | 869,317 | $1000K | SEC Form 4 |
| 2025-12-17 | 2025-12-15 | Walker Karen Marie | Insider | sell | $12.20 | 23,998 | 22,636 | $293K | SEC Form 4 |
| 2025-12-17 | 2025-12-15 | Walker Karen Marie | Insider | buy | $4.83 | 23,998 | 46,634 | $116K | SEC Form 4 |
KYTX contract awards, year to date.
Public federal awards linked to this ticker.
KYTX lobbying filings, year to date.
Registered lobbying filings matched to Kyverna Therapeutics Inc.